Citation
Sahin, Ugur, et al. "COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses." Nature, vol. 586, no. 7830, 2020, pp. 594-599.
Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594-599.
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., Brachtendorf, S., Lörks, V., Sikorski, J., Hilker, R., Becker, D., Eller, A. K., Grützner, J., Boesler, C., Rosenbaum, C., ... Türeci, Ö. (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature, 586(7830), 594-599. https://doi.org/10.1038/s41586-020-2814-7
Sahin U, et al. COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses. Nature. 2020;586(7830):594-599. PubMed PMID: 32998157.
TY - JOUR
T1 - COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.
AU - Sahin,Ugur,
AU - Muik,Alexander,
AU - Derhovanessian,Evelyna,
AU - Vogler,Isabel,
AU - Kranz,Lena M,
AU - Vormehr,Mathias,
AU - Baum,Alina,
AU - Pascal,Kristen,
AU - Quandt,Jasmin,
AU - Maurus,Daniel,
AU - Brachtendorf,Sebastian,
AU - Lörks,Verena,
AU - Sikorski,Julian,
AU - Hilker,Rolf,
AU - Becker,Dirk,
AU - Eller,Ann-Kathrin,
AU - Grützner,Jan,
AU - Boesler,Carsten,
AU - Rosenbaum,Corinna,
AU - Kühnle,Marie-Cristine,
AU - Luxemburger,Ulrich,
AU - Kemmer-Brück,Alexandra,
AU - Langer,David,
AU - Bexon,Martin,
AU - Bolte,Stefanie,
AU - Karikó,Katalin,
AU - Palanche,Tania,
AU - Fischer,Boris,
AU - Schultz,Armin,
AU - Shi,Pei-Yong,
AU - Fontes-Garfias,Camila,
AU - Perez,John L,
AU - Swanson,Kena A,
AU - Loschko,Jakob,
AU - Scully,Ingrid L,
AU - Cutler,Mark,
AU - Kalina,Warren,
AU - Kyratsous,Christos A,
AU - Cooper,David,
AU - Dormitzer,Philip R,
AU - Jansen,Kathrin U,
AU - Türeci,Özlem,
Y1 - 2020/09/30/
PY - 2020/07/16/received
PY - 2020/09/22/accepted
PY - 2020/10/1/pubmed
PY - 2020/10/1/medline
PY - 2020/9/30/entrez
SP - 594
EP - 599
JF - Nature
JO - Nature
VL - 586
IS - 7830
N2 - An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein1. Here we present antibody and T cell responses after vaccination with BNT162b1 from a second, non-randomized open-label phase I/II trial in healthy adults, 18-55 years of age. Two doses of 1-50 μg of BNT162b1 elicited robust CD4+ and CD8+ T cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those seen in serum from a cohort of individuals who had recovered from COVID-19. Geometric mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were 0.7-fold (1-μg dose) to 3.5-fold (50-μg dose) those of the recovered individuals. Immune sera broadly neutralized pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (TH1)-skewed T cell immune responses with RBD-specific CD8+ and CD4+ T cell expansion. Interferon-γ was produced by a large fraction of RBD-specific CD8+ and CD4+ T cells. The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
SN - 1476-4687
UR - https://www.unboundmedicine.com/medline/citation/32998157/full_citation
L2 - https://doi.org/10.1038/s41586-020-2814-7
DB - PRIME
DP - Unbound Medicine
ER -
